[ET Net News Agency, 23 August 2019] Jefferies Research raised its target price for
Yichang HEC Changjiang Pharmaceutical (01558) to HK$53 from HK$50 and maintained its "buy"
rating.
The research house said Kewei delivered extraordinary growth in 1H but at the same time,
selling expenses also surged significantly within the period due to the sales team and
network expansion.
Management is confident about the outlook of Kewei in the next three years. Recombinant
insulin and Yimitasvir expected to be approved in the next six months, and together with
the generics, HEC is working towards a diversified portfolio.
Jefferies adjusted its core net profit upward by 12.3%/26.2% in 2019/20. It now expects
core net profit CAGR of 29.2% in 2018-21. (KL)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01558 HEC CJ PHARM
Nominal 
12.960 -0.120 (-0.917%) Research Report
23/08/2019 16:08
{I-bank focus}Jefferies raises HEC Pharm (01558) to HK$53
| Remark: | Real time quote last updated: 30/04/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |